Luminespib (NVP-AUY922)

Name: Luminespib (NVP-AUY922)
Brand: Selleck Chemicals
SKU: S1069
Rating: 5 (70 reviews)

For research use only.

Catalog No.S1069 Synonyms: AUY-922

70 publications

Luminespib (NVP-AUY922) Chemical Structure

CAS No. 747412-49-3

Luminespib (AUY-922, NVP-AUY922) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Luminespib (AUY-922, NVP-AUY922) effectively downregulates and destabilizes the IGF-1Rβ protein and results in growth inhibition, autophagy and apoptosis. Phase 2.

Selleck's Luminespib (NVP-AUY922) has been cited by 70 publications

Cancer Cell, 2020, 37(3):371-386

PubMed: 32109374 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Cell, 2012, 31;150(5):987-1001.

PubMed: 22939624 ( click the link to review the publication )

Nat Commun, 2020, 11(1):562

PubMed: 31992715 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Front Immunol, 2020,

PubMed: 32903557 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(13):E4740

PubMed: 32635192 ( click the link to review the publication )

Int J Mol Med, 2020, 45(5):1543-1553

PubMed: 32323753 ( click the link to review the publication )

Exp Lung Res, 2020, 46(6):203-216

PubMed: 32400213 ( click the link to review the publication )

Korean J Physiol Pharmacol, 2020, 1;24(3):241-248

PubMed: 32395075 ( click the link to review the publication )

Nat Commun, 2019, 10(1):402

PubMed: 30679438 ( click the link to review the publication )

J Neurosci, 2019, 39(17):3332-3344

PubMed: 30696728 ( click the link to review the publication )

Cells, 2019, 8(8)

PubMed: 31370342 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(11):2097-2110

PubMed: 31395684 ( click the link to review the publication )

Front Endocrinol (Lausanne), 2019, 10:487

PubMed: 31379752 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):102

PubMed: 30678647 ( click the link to review the publication )

Clin Exp Med, 2019, 10.1007/s10238-019-00587-2

PubMed: 31650359 ( click the link to review the publication )

Hepatology, 2019, 69(2):573-586

PubMed: 29356025 ( click the link to review the publication )

ACS Chem Neurosci, 2019, 10(6):2890-2902

PubMed: 31017387 ( click the link to review the publication )

Transl Lung Cancer Res, 2019, 8(4):340-351

PubMed: 31555510 ( click the link to review the publication )

Autophagy, 2018, 14(6):958-971

PubMed: 29561705 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(24):6548-6555

PubMed: 30154228 ( click the link to review the publication )
Mol Syst Biol, 2018, 14(3):e7858

PubMed: 29507054 ( click the link to review the publication )

J Immunol, 2018,

PubMed: 29445007 ( click the link to review the publication )

J Cell Mol Med, 2018, 22(3):1792-1804

PubMed: 29363851 ( click the link to review the publication )

BMB Rep, 2018, 51(12):660-665

PubMed: 30591093 ( click the link to review the publication )

Oncotarget, 2018,

PubMed: 29599910 ( click the link to review the publication )

Cancer Lett, 2017, 411:19-26

PubMed: 28987383 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2017, 80(4):673-684

PubMed: 28779264 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 487(2):313-319

PubMed: 28412368 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:2219-2226

PubMed: 28458565 ( click the link to review the publication )

Sci Rep, 2017, 7(1):201

PubMed: 28298630 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58771-58780

PubMed: 28938595 ( click the link to review the publication )

Cancer Lett, 2016, 372(1):75-81

PubMed: 26723875 ( click the link to review the publication )

Sci Rep, 2016, 6:33710

PubMed: 27641368 ( click the link to review the publication )

J Biol Chem, 2016, 291(19):10332-46

PubMed: 26957545 ( click the link to review the publication )

Horm Cancer, 2016, 7(2):114-26

PubMed: 26858237 ( click the link to review the publication )

PeerJ, 2016, 4:e1683

PubMed: 26893968 ( click the link to review the publication )

Medicinal Chemistry Research, 2016, 10.1007/s00044-016-1553-7

PubMed: ( click the link to review the publication )

Oncotarget, 2016, 7(31):49597-49610

PubMed: 27391062 ( click the link to review the publication )

Immun Inflamm Dis, 2016, 4(4):463-473

PubMed: 27980780 ( click the link to review the publication )

PLoS Negl Trop Dis, 2015, 8(2):e2699

PubMed: 24551261 ( click the link to review the publication )

Biochimica et Biophysica Acta, 2015, 10.1016/j.bbamcr.2015.05.012

PubMed: 25982393 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2015, 309(12):L1410-9

PubMed: 26498249 ( click the link to review the publication )

Int J Biol Sci, 2015, 11(8):923-34

PubMed: 26157347 ( click the link to review the publication )

Molecules, 2015, 20(1):1643-60

PubMed: 25608045 ( click the link to review the publication )
Biochemistry, 2015, 10.1021/acs.biochem.5b00148

PubMed: 25905789 ( click the link to review the publication )

PLoS One, 2015, 10(3):e0119832

PubMed: 25780909 ( click the link to review the publication )

Oncol Lett, 2015, 10(2):941-945

PubMed: 26622600 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26416354 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Oncoscience, 2015, 2(4):419-427

PubMed: 26097875 ( click the link to review the publication )

Nat Commun, 2014, 5:3361

PubMed: 24553445 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(15):E1528-37

PubMed: 24706778 ( click the link to review the publication )

Int J Cancer, 2014, 135(10):2462-74

PubMed: 24706460 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2014, 50(1):170-9

PubMed: 23972231 ( click the link to review the publication )

Cell Signal, 2014, 27(2):293-305

PubMed: 25446253 ( click the link to review the publication )

PLoS One, 2014, 9(12):e114506

PubMed: 25503774 ( click the link to review the publication )

Tumour Biol, 2014, 35(8):8193-9

PubMed: 24850175 ( click the link to review the publication )

Mol Oncol, 2013, 7(6):1093-102

PubMed: 23993685 ( click the link to review the publication )

J Biol Chem, 2013, 288(23):16308-20

PubMed: 23599433 ( click the link to review the publication )

J Proteome Res, 2013, 12(8):3697-706

PubMed: 23763277 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2013, 273(2):401-9

PubMed: 24090817 ( click the link to review the publication )

PLoS Pathog, 2012, 8(11):e1003048

PubMed: 23209418 ( click the link to review the publication )

Br J Haematol, 2012, 160(4):465-76

PubMed: 23252346 ( click the link to review the publication )

Mol Cell Biochem, 2012, 370(1-2):141-50

PubMed: 22865466 ( click the link to review the publication )

American Society of Clinical Oncology Annual Meeting, 2012, Chicago

PubMed: ( click the link to review the publication )

Mol Cancer, 2011, 10:125

PubMed: 21962244 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HSP (HSP90) Inhibitors

Biological Activity

Description

Targets

HSP90α ^[1] (Cell-free assay)	HSP90β ^[1] (Cell-free assay)
13 nM	21 nM

In vitro

NVP-AUY922 inhibits proliferation of various human cancer cell lines in vitro, with an average GI50 of 9 nM. ^[1] The IC50 values of NVP-AUY922 fall in the range of 2 to 40 nM in these gastric cancer cell lines. IC50 value for the BEAS-2B cells is 28.49 nM. Treatment with NVP-AUY922 does not influence the expression of HSP90, but expression of HSP70 gets elevated by NVP-AUY922 treatment. NVP-AUY922 increases the binding of HSP70 to HSP90. NVP-AUY922 causes p23 dissociation from the HSP90 complex and can then recruit HSP70 to the HSP90 complex. ^[1] After the treatment with NVP-AUY922, expression of receptor tyrosine kinases including VEGFR1, 2, 3 and PDGFRɑ is decreased. A decrease is also noticed in the expression of Akt and phospho-Akt. Meanwhile, treatment with NVP-AUY922 causes decreased expression of HER-2 in NCI-N87 cells. NVP-AUY922 treatment results in binding of HSP90 to client proteins and setting them up as targets for degradation by the proteasome. NVP-AUY922 can influence cell growth by affecting multiple signaling pathways. In addition, treatment with the proteasome inhibitor, MG132, restores expression of thymidylate synthase, which is decreased by NVP-AUY922. NVP-AUY922 increases the expression of cleaved caspase-3 leading to apoptosis in HSC-2 cells.^[1]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
CMK	M1HJVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7WcXBKSzVyPUCuNFAxOTJ3IN88US=>	M3HVUXNCVkeHUh?=
MV-4-11	NUnVTpF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2nKUmlEPTB;MD6wNFA2PThizszN	MkfPV2FPT0WU
NALM-6	MlfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIDSdWhKSzVyPUCuNFAxQDR{IN88US=>	MnTnV2FPT0WU
HOS	NULRSXJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTBwMECxN\|gh\|ryP	NFjhT2JUSU6JRWK=
HT-144	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrMO2pEUUN3ME2wMlAxOTV3IN88US=>	MYfTRW5ITVJ?
SW1710	Ml3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVnHXpNnUUN3ME2wMlAxOTh4IN88US=>	M3r6ZXNCVkeHUh?=
TE-8	M2[2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PHc2lEPTB;MD6wNFI{PyEQvF2=	Mk\qV2FPT0WU
ES1	NH:2fZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXyyO3VXUUN3ME2wMlAxOjZ4IN88US=>	M2\vZ3NCVkeHUh?=
CCF-STTG1	NVzp[HFnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3HXUmlEPTB;MD6wNFI6PyEQvF2=	NYXyXFJiW0GQR1XS
PSN1	NEWyb5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVTv[pZ2UUN3ME2wMlAxOzF6IN88US=>	MkHyV2FPT0WU
CAL-51	M3;aV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\UOnVKSzVyPUCuNFA{OjVizszN	NFzWUmVUSU6JRWK=
MCF7	M4PxTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn;qTWM2OD1yLkCwN\|M2KM7:TR?=	NX3veoJXW0GQR1XS
SK-HEP-1	NYfnWFFMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\aVGw6UUN3ME2wMlAxOzN4IN88US=>	Moj1V2FPT0WU
LCLC-103H	M16wbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLjTWM2OD1yLkCwOFMh\|ryP	MmLPV2FPT0WU
HMV-II	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHLJPGVKSzVyPUCuNFA1PDlizszN	MVfTRW5ITVJ?
MES-SA	Mk\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXrQZnZIUUN3ME2wMlAxPDV{IN88US=>	MXvTRW5ITVJ?
SK-LMS-1	MmfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4LpVWlEPTB;MD6wNFQ2QCEQvF2=	M2LMWHNCVkeHUh?=
639-V	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\JTWM2OD1yLkCwOFg2KM7:TR?=	MYHTRW5ITVJ?
SIG-M5	NIn4c29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;zXVdNUUN3ME2wMlAxPDh7IN88US=>	NFvlZlBUSU6JRWK=
LOUCY	MkXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIPpcYNKSzVyPUCuNFA2ODVizszN	NF:1UFhUSU6JRWK=
HSC-2	NEHNOlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1HTPWlEPTB;MD6wNFUyQCEQvF2=	M1XBXXNCVkeHUh?=
EW-13	NWLhT21lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{TDTWlEPTB;MD6wNFUyQCEQvF2=	MV;TRW5ITVJ?
RT-112	M{fNN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3rkVGlEPTB;MD6wNFU{PSEQvF2=	NXXXenpEW0GQR1XS
NKM-1	M2nBbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoHSTWM2OD1yLkCwOVQ4KM7:TR?=	MWLTRW5ITVJ?
KYSE-180	NEi5T5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXvTWM2OD1yLkCwOVg3KM7:TR?=	NGjuZZhUSU6JRWK=
SW1783	M1zFPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1PjSWlEPTB;MD6wNFU6OSEQvF2=	MYjTRW5ITVJ?
A431	M2PYbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3\yUWlEPTB;MD6wNFYxPyEQvF2=	M1j4bXNCVkeHUh?=
SK-OV-3	NWTiToROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTBwMEC2N{DPxE1?	MknFV2FPT0WU
RPMI-7951	MkniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1L2O2lEPTB;MD6wNFY{OSEQvF2=	M4LlT3NCVkeHUh?=
Capan-2	MlTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkHtTWM2OD1yLkCwOlM5KM7:TR?=	NYDKSYFGW0GQR1XS
HSC-3	M3\ydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkG5TWM2OD1yLkCwOlQyKM7:TR?=	NG\OWHZUSU6JRWK=
786-0	NX\nfXNKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFTTN2RKSzVyPUCuNFA3PjNizszN	M3rN[nNCVkeHUh?=
Daoy	Mne1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF3GVVBKSzVyPUCuNFA3QTVizszN	NYDuU\|Q1W0GQR1XS
KGN	NWjDfmZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGn0RlBKSzVyPUCuNFA4ODNizszN	NGWyZ2NUSU6JRWK=
EW-16	NEOwSpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjFPY9MUUN3ME2wMlAxPzR7IN88US=>	NUTBfXRQW0GQR1XS
EW-7	M4n6Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1jEPWlEPTB;MD6wNFc2PCEQvF2=	M4TVRnNCVkeHUh?=
IGROV-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M33oPGlEPTB;MD6wNFgyPCEQvF2=	MUXTRW5ITVJ?
8505C	NFWzWphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlexTWM2OD1yLkCwPFIyKM7:TR?=	M2HLbnNCVkeHUh?=
RKO	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\BOpNKSzVyPUCuNFA5OjZizszN	M33seHNCVkeHUh?=
GDM-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXvFRVZmUUN3ME2wMlAxQDRizszN	NGPLVJdUSU6JRWK=
IST-MEL1	M1P6PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2P1NWlEPTB;MD6wNFg2OiEQvF2=	NEnl[\|BUSU6JRWK=
RPMI-6666	NIfGemJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4C4NWlEPTB;MD6wNFg2OiEQvF2=	M2\nO3NCVkeHUh?=
SNG-M	NFnySWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTBwMEC4OVYh\|ryP	M3vwPHNCVkeHUh?=
KS-1	NXnHNHRoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTBwMEC4OVkh\|ryP	NX2xdVZNW0GQR1XS
RXF393	NHriR5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTBT5JKUUN3ME2wMlAxQDZizszN	NI\sPYNUSU6JRWK=
CAL-12T	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXNUJVKSzVyPUCuNFA6OjJizszN	NWfZenR2W0GQR1XS
BFTC-905	NITBbYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\TTWM2OD1yLkCwPVM5KM7:TR?=	NHv2b5ZUSU6JRWK=
SK-MES-1	NFrPSoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEPhXWpKSzVyPUCuNFA6PDVizszN	NWPTdVRRW0GQR1XS
BB30-HNC	NE\2NZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoTkTWM2OD1yLkCwPVUzKM7:TR?=	M1jue3NCVkeHUh?=
AN3-CA	NYDseGFjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2C4dmlEPTB;MD6wNVAyPyEQvF2=	NGrGR2NUSU6JRWK=
EFO-27	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTBwMEGwNVch\|ryP	MUXTRW5ITVJ?
G-401	NVPuNY5yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUT0XIpbUUN3ME2wMlAyODJ3IN88US=>	NHTUSGtUSU6JRWK=
BPH-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHTCbXVKSzVyPUCuNFExOyEQvF2=	M4f0PHNCVkeHUh?=
NCI-H727	NXXtb\|ZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{XLOGlEPTB;MD6wNVA{KM7:TR?=	MoLlV2FPT0WU
SNU-423	M1ewfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4TOOmlEPTB;MD6wNVA2OyEQvF2=	NIn6WVhUSU6JRWK=
KYSE-270	M2LqRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml7wTWM2OD1yLkCxNFU6KM7:TR?=	MmHaV2FPT0WU
AGS	M4LO[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfRUoRKSzVyPUCuNFExPjFizszN	NWezWZd{W0GQR1XS
NCI-H2228	NV;kOFlyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDETWM2OD1yLkCxNFY1KM7:TR?=	MnjrV2FPT0WU
SW954	NYqxVGFYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGK3[FJKSzVyPUCuNFExPzFizszN	NUTzVoFOW0GQR1XS
769-P	M3fweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7xN4FKSzVyPUCuNFExPzNizszN	Mm\JV2FPT0WU
BB49-HNC	M1[wPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTBwMEGwO\|ch\|ryP	M3i4c3NCVkeHUh?=
IA-LM	M1XYc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTBwMEGwPFYh\|ryP	M2[0V3NCVkeHUh?=
NB69	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkXaTWM2OD1yLkCxNVAzKM7:TR?=	MmP3V2FPT0WU
C8166	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUD0PYoxUUN3ME2wMlAyOTJ7IN88US=>	NFHWRpJUSU6JRWK=
NCI-H1299	Mn;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NETDeYFKSzVyPUCuNFEyPTRizszN	MnXPV2FPT0WU
YKG-1	Moj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2P2fWlEPTB;MD6wNVE3KM7:TR?=	MWLTRW5ITVJ?
PANC-03-27	M{nZV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHiTWM2OD1yLkCxNVYzKM7:TR?=	MlnTV2FPT0WU
YT	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXjXcWQyUUN3ME2wMlAyOTd7IN88US=>	Mo[xV2FPT0WU
CAL-85-1	MknlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTBwMEGxPVIh\|ryP	MWLTRW5ITVJ?
GT3TKB	NHGxbW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\xc\|R{UUN3ME2wMlAyOjB{IN88US=>	MV3TRW5ITVJ?
BB65-RCC	NIHkWXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnHkTWM2OD1yLkCxNlA1KM7:TR?=	NXnvR29FW0GQR1XS
ES6	M3;hOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{jFTGlEPTB;MD6wNVI3OSEQvF2=	NYDDOnVYW0GQR1XS
MHH-ES-1	NVi4[2g3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTBwMEGyOlMh\|ryP	M1qwNXNCVkeHUh?=
QIMR-WIL	MmP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV75UWd[UUN3ME2wMlAyOjZ7IN88US=>	M{DU[HNCVkeHUh?=
SNU-C2B	M{DLNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M37DS2lEPTB;MD6wNVI4OiEQvF2=	M{jCbXNCVkeHUh?=
OCI-AML2	NGm0XmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTBwMEGyPFEh\|ryP	NV;CR3c5W0GQR1XS
DU-145	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTBwMEGyPUDPxE1?	NEXvbHVUSU6JRWK=
SW982	Mnf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWjRNVB{UUN3ME2wMlAyOjl\|IN88US=>	NUKwSXp6W0GQR1XS
MFH-ino	M4jremdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3nvbGlEPTB;MD6wNVI6OyEQvF2=	MXjTRW5ITVJ?
A427	NV;lTHlrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTBwMEGyPVkh\|ryP	MUjTRW5ITVJ?
LCLC-97TM1	NWf4WYJYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWTSXZhSUUN3ME2wMlAyOyEQvF2=	NV;yPHJLW0GQR1XS
AM-38	NUXxc3FtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHWTVlKSzVyPUCuNFE{ODJizszN	M4HsdHNCVkeHUh?=
K5	NXzjcpMxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIfqO3NKSzVyPUCuNFE{ODhizszN	M3zDT3NCVkeHUh?=
T84	NVLlN41kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmPGTWM2OD1yLkCxN\|MyKM7:TR?=	MWPTRW5ITVJ?
TE-15	NHfPd5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYqwboJSUUN3ME2wMlAyOzN4IN88US=>	MUfTRW5ITVJ?
NCI-H460	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3y2b2lEPTB;MD6wNVM{PiEQvF2=	M3roZnNCVkeHUh?=
NTERA-S-cl-D1	M{TT[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{XFTWlEPTB;MD6wNVM{QSEQvF2=	MorHV2FPT0WU
KYSE-450	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1nheGlEPTB;MD6wNVM1QSEQvF2=	MlXPV2FPT0WU
H4	MnKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LLOmlEPTB;MD6wNVM3PiEQvF2=	NF7zc29USU6JRWK=
LC-2-ad	NUTV[nN3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1HXVGlEPTB;MD6wNVM4KM7:TR?=	M2TlXHNCVkeHUh?=
GAMG	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvtTWM2OD1yLkCxN\|cyKM7:TR?=	NYjzXW5OW0GQR1XS
TK10	MnnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEHZUXpKSzVyPUCuNFE{QDJizszN	NULJd45yW0GQR1XS
NCI-H2122	NHfHZY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3;IV2lEPTB;MD6wNVM5PCEQvF2=	Mmm2V2FPT0WU
KM12	NGXEOY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn3VTWM2OD1yLkCxN\|k6KM7:TR?=	MnH2V2FPT0WU
CAL-39	MlG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTBwMEG0NkDPxE1?	NVOxfFZQW0GQR1XS
RPMI-2650	M{[wVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XXeWlEPTB;MD6wNVQ{OiEQvF2=	MWDTRW5ITVJ?
KYSE-510	NFO3dZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlfDTWM2OD1yLkCxOFQzKM7:TR?=	MXLTRW5ITVJ?
KALS-1	NXrBZoRKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXe1bYl{UUN3ME2wMlAyPDZ4IN88US=>	NY\6XVZEW0GQR1XS
NCI-H1648	M1XLd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnDVpNKSzVyPUCuNFE1QTlizszN	MlH5V2FPT0WU
ES4	NXzTfXZmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1T5RWlEPTB;MD6wNVUxOiEQvF2=	NVTEUndNW0GQR1XS
C-33-A	M1vVeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4ftOmlEPTB;MD6wNVUxQSEQvF2=	NViyeWRCW0GQR1XS
MIA-PaCa-2	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HhZmlEPTB;MD6wNVUxQSEQvF2=	NIXsZ\|ZUSU6JRWK=
Becker	NGPZepdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH3TcFhKSzVyPUCuNFE2OTRizszN	MnfGV2FPT0WU
HOP-62	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{m5[mlEPTB;MD6wNVU1OiEQvF2=	NF;xRWtUSU6JRWK=
TE-1	MmjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4GxTWlEPTB;MD6wNVU5OSEQvF2=	M1jiVXNCVkeHUh?=
KYSE-410	M1KyfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkDiTWM2OD1yLkCxOVg3KM7:TR?=	M{nhbXNCVkeHUh?=
NOS-1	M3\Sb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{HSN2lEPTB;MD6wNVU6OyEQvF2=	MYLTRW5ITVJ?
MEL-HO	NVfhbGVOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1qwPGlEPTB;MD6wNVY1OyEQvF2=	MkX0V2FPT0WU
NCI-H1650	M2rSeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1HmbWlEPTB;MD6wNVY1PiEQvF2=	NXfSWXBrW0GQR1XS
VMRC-RCZ	NYixXIJyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvIco1KSzVyPUCuNFE3PTFizszN	NEnmNlRUSU6JRWK=
HuP-T3	NGTtR3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVXJR\|UxRTBwMEG2OVMh\|ryP	MVfTRW5ITVJ?
ACN	M4TEUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlr6TWM2OD1yLkCxOlU4KM7:TR?=	MlnQV2FPT0WU
MEL-JUSO	MknuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUf1VXBnUUN3ME2wMlAyPjhzIN88US=>	NYW0RoNXW0GQR1XS
HT-1197	NYO0dldvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTBwMEG2PFUh\|ryP	MVHTRW5ITVJ?
NCI-H2030	NXnPb5d[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3fRV2lEPTB;MD6wNVY6PyEQvF2=	MoDQV2FPT0WU
A4-Fuk	Ml7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGL5V49KSzVyPUCuNFE4ODJizszN	MX7TRW5ITVJ?
NCI-H292	M{TVRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHyyeWJKSzVyPUCuNFE4ODlizszN	NFHlTmFUSU6JRWK=
A2780	MnnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofwTWM2OD1yLkCxO\|E2KM7:TR?=	NWf6fIZXW0GQR1XS
SF295	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4rYZmlEPTB;MD6wNVczOSEQvF2=	NWHlWmtXW0GQR1XS
NCI-H810	NYXxXlJRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTBwMEG3NlQh\|ryP	NYWyb2o3W0GQR1XS
ALL-PO	MoD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn:zTWM2OD1yLkCxO\|M2KM7:TR?=	NEKzOplUSU6JRWK=
MC-IXC	M2fTdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVXqSplJUUN3ME2wMlAyPzN4IN88US=>	MVLTRW5ITVJ?
NY	NELYPWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTBwMEG3OEDPxE1?	MXnTRW5ITVJ?
OMC-1	M2Du[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjybmFKSzVyPUCuNFE4PTFizszN	M{O3e3NCVkeHUh?=
PANC-10-05	NIrhfVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTBwMEG3OVUh\|ryP	MoPaV2FPT0WU
NCI-H2342	NH6wO5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTBwMEG3OVgh\|ryP	NInKXGdUSU6JRWK=
HGC-27	NVnJWFZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHLKXlRKSzVyPUCuNFE4PThizszN	NEi5TIVUSU6JRWK=
TE-12	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYq1RpVQUUN3ME2wMlAyPzd3IN88US=>	MUnTRW5ITVJ?
MOLT-16	MoD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHjaR5BKSzVyPUCuNFE4QDhizszN	NHWwN3JUSU6JRWK=
HL-60	NV7meGFXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmO2TWM2OD1yLkCxPFA4KM7:TR?=	MmPqV2FPT0WU
OVCAR-5	M3vJbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkLpTWM2OD1yLkCxPFEzKM7:TR?=	MXfTRW5ITVJ?
SK-LU-1	NVv5VJl[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DmWWlEPTB;MD6wNVg1PiEQvF2=	NX;3eo9NW0GQR1XS
MG-63	MnrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnfpTWM2OD1yLkCxPFc1KM7:TR?=	NInFUXNUSU6JRWK=
8-MG-BA	M3LYU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTBwMEG4PFQh\|ryP	MYjTRW5ITVJ?
COR-L105	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M13nemlEPTB;MD6wNVkyOSEQvF2=	MWPTRW5ITVJ?
BHY	Mn\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoC0TWM2OD1yLkCxPVEzKM7:TR?=	NITuUXFUSU6JRWK=
SW620	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTBwMEG5NVUh\|ryP	NUGzd5pQW0GQR1XS
PC-14	M4DURWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\oTWM2OD1yLkCxPVM1KM7:TR?=	NWH6VIVuW0GQR1XS
NCI-H522	NILmWoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmjDTWM2OD1yLkCxPVM6KM7:TR?=	M2jQfXNCVkeHUh?=
OE19	NFfCOGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTBwMEG5OUDPxE1?	NXzZc5VWW0GQR1XS
RVH-421	NVXoXFlwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmrPTWM2OD1yLkCxPVU4KM7:TR?=	M1raVXNCVkeHUh?=
TE-10	NGHXTmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXHTWM2OD1yLkCxPVc4KM7:TR?=	M{ns[3NCVkeHUh?=
A101D	NETrRppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTBwMEG5PFch\|ryP	NILKVIZUSU6JRWK=
HUTU-80	MnHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTBwMEKwNFQh\|ryP	MoLtV2FPT0WU
KYSE-140	NH\IVGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTBwMEKwNlQh\|ryP	NYG3OGw5W0GQR1XS
SNU-449	NF;WRndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nxe2lEPTB;MD6wNlAzPiEQvF2=	NIPWOoJUSU6JRWK=
697	NV;ZfGR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTBwMEKwN\|Eh\|ryP	MYjTRW5ITVJ?
SJSA-1	NH;0NlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnB[phKSzVyPUCuNFIxOzdizszN	M{nT[3NCVkeHUh?=
IGR-1	M3fRVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoPDTWM2OD1yLkCyNFUh\|ryP	NVywTZJ3W0GQR1XS
GCIY	Mn3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIrrN4lKSzVyPUCuNFIxPTVizszN	MV;TRW5ITVJ?
REH	M2O3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTBwMEKwOVkh\|ryP	M1[wVnNCVkeHUh?=
A204	M1vUdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkDoTWM2OD1yLkCyNVE2KM7:TR?=	MnfuV2FPT0WU
A388	M17hdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnG2TWM2OD1yLkCyNVE2KM7:TR?=	M2\IbXNCVkeHUh?=
NCI-H650	NY[2SFlJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXzJR\|UxRTBwMEKxNVch\|ryP	MnHuV2FPT0WU
SW626	MmfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLsN\|JRUUN3ME2wMlAzOTJizszN	M4S2b3NCVkeHUh?=
DoTc2-4510	NH:5[IVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnryTWM2OD1yLkCyNVIzKM7:TR?=	M3jybXNCVkeHUh?=
HCE-4	NGjicIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRTBwMEKxOFUh\|ryP	M3TzT3NCVkeHUh?=
DU-4475	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkHZTWM2OD1yLkCyNVUh\|ryP	MoTRV2FPT0WU
A375	M{TyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUPPeJJuUUN3ME2wMlAzOTdzIN88US=>	NWW1Opg4W0GQR1XS
GB-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXm2dot2UUN3ME2wMlAzOTh6IN88US=>	NF;ySZpUSU6JRWK=
CHP-212	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXMTWM2OD1yLkCyNlEzKM7:TR?=	MmHsV2FPT0WU
HT-1080	M{jVcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoO2TWM2OD1yLkCyNlE1KM7:TR?=	M2D1NnNCVkeHUh?=
M059J	MnPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTBwMEKyOFEh\|ryP	NUPUcpFrW0GQR1XS
NMC-G1	NYXo[nNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{TldWlEPTB;MD6wNlI5KM7:TR?=	NFX2[ZpUSU6JRWK=
MRK-nu-1	NEfJNHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NITHS21KSzVyPUCuNFI{KM7:TR?=	NY\IcW92W0GQR1XS
MFE-296	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLwTWM2OD1yLkCyN\|IzKM7:TR?=	MULTRW5ITVJ?
LOXIMVI	MmDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTBwMEKzNlMh\|ryP	M331N3NCVkeHUh?=
CGTH-W-1	NXzCcYdwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmjsTWM2OD1yLkCyN\|I5KM7:TR?=	M3\kdXNCVkeHUh?=
CCRF-CEM	NU\UeGFZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV3JR\|UxRTBwMEKzNlkh\|ryP	NYW5Ro5RW0GQR1XS
ACHN	NH;CRZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3myc2lEPTB;MD6wNlM1PSEQvF2=	NX3M[FVyW0GQR1XS
NCI-H1355	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXuxSVlKUUN3ME2wMlAzPDBzIN88US=>	NI\5b4hUSU6JRWK=
NCI-H1651	M1TjcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLjTWM2OD1yLkCyOFMyKM7:TR?=	MUnTRW5ITVJ?
KINGS-1	M4TZV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTBwMEK0N\|Mh\|ryP	MWPTRW5ITVJ?
LS-123	NV\3RWFvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPLeIJKSzVyPUCuNFI1OzVizszN	M{DC[nNCVkeHUh?=
SNB75	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTBwMEK0OlYh\|ryP	M1XaRXNCVkeHUh?=
C3A	NEfaZodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjsTlgzUUN3ME2wMlAzPDd3IN88US=>	MWnTRW5ITVJ?
HO-1-N-1	NHSyTWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4jT[2lEPTB;MD6wNlU1QSEQvF2=	NUHtcHdpW0GQR1XS
EHEB	M1vaTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{XkXmlEPTB;MD6wNlU2PSEQvF2=	MW\TRW5ITVJ?
CAL-62	NVrTT4w6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHj0T2tKSzVyPUCuNFI2PyEQvF2=	MWjTRW5ITVJ?
U-118-MG	Ml60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkjxTWM2OD1yLkCyOVc3KM7:TR?=	NHjSU5pUSU6JRWK=
HN	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEfUXYpKSzVyPUCuNFI2QTNizszN	MorVV2FPT0WU
HTC-C3	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnf5TWM2OD1yLkCyOlA4KM7:TR?=	NIfkZmJUSU6JRWK=
KYSE-520	NIL1U2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmK5TWM2OD1yLkCyOlE{KM7:TR?=	MnHEV2FPT0WU
MZ1-PC	M1X6Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1XtWGlEPTB;MD6wNlY{QSEQvF2=	MUnTRW5ITVJ?
BCPAP	MnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF7DOYlKSzVyPUCuNFI3PDZizszN	M{TuPXNCVkeHUh?=
RD	NU\qTYJzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PjTmlEPTB;MD6wNlY2QCEQvF2=	NW\SU2tEW0GQR1XS
NCI-H520	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYfOUXdCUUN3ME2wMlAzPjZ2IN88US=>	MV;TRW5ITVJ?
LXF-289	NGDX[IVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3zSotIUUN3ME2wMlAzPjZ6IN88US=>	NWrQS2c2W0GQR1XS
G-361	Mkm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFrPcpBKSzVyPUCuNFI3PzdizszN	NWD1W4RUW0GQR1XS
LB996-RCC	NEKzd\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M322OmlEPTB;MD6wNlcyKM7:TR?=	M4[5S3NCVkeHUh?=
COR-L23	M4rZW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTpbFhEUUN3ME2wMlAzPzF\|IN88US=>	MWrTRW5ITVJ?
GP5d	M{OxbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXrJR\|UxRTBwMEK3NlMh\|ryP	NYDjeINpW0GQR1XS
SW1990	Mni1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIi4[pRKSzVyPUCuNFI4OjRizszN	M3\qc3NCVkeHUh?=
PA-1	NGXuWGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mkj6TWM2OD1yLkCyO\|U2KM7:TR?=	M17JenNCVkeHUh?=
NCI-H2009	M4HzWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTBwMEK3OkDPxE1?	M{TCfnNCVkeHUh?=
SR	M37odmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYD4S3B6UUN3ME2wMlAzPzh3IN88US=>	MUPTRW5ITVJ?
Ca9-22	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTBwMEK3PVYh\|ryP	NEX0[oFUSU6JRWK=
SCC-15	NUHJeIVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\POnFRUUN3ME2wMlAzQDBzIN88US=>	NFTwe3JUSU6JRWK=
ETK-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXnsSIdWUUN3ME2wMlAzQDB4IN88US=>	MofBV2FPT0WU
SCC-4	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTBwMEK4NFkh\|ryP	NFXy[VdUSU6JRWK=
5637	NHPzdFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHQTWM2OD1yLkCyPFIzKM7:TR?=	MVPTRW5ITVJ?
EW-1	NFXhSHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmfmTWM2OD1yLkCyPFIzKM7:TR?=	MlvPV2FPT0WU
SW962	Ml:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUXuNlhuUUN3ME2wMlAzQDV{IN88US=>	NX60cHRXW0GQR1XS
HCE-T	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjZV\|M4UUN3ME2wMlAzQDZizszN	NYXD[FBTW0GQR1XS
NCI-H2405	NUm2UFZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVTMTmVCUUN3ME2wMlAzQDh5IN88US=>	M4DDdXNCVkeHUh?=
A2058	NFX4UJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRTBwMEK5Nlkh\|ryP	M4OxVXNCVkeHUh?=
HCC2998	NXvlT2V6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTBwMEK5OFUh\|ryP	MlPoV2FPT0WU
ONS-76	NWDL[oR7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYf3SGs{UUN3ME2wMlAzQTV2IN88US=>	MmjYV2FPT0WU
DBTRG-05MG	MnPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTBwMEK5OVUh\|ryP	MmfUV2FPT0WU
HuCCT1	NGXLe5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjwbYl{UUN3ME2wMlAzQTZzIN88US=>	M2\TU3NCVkeHUh?=
J82	NI\NW\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXG3[WhUUUN3ME2wMlA{ODB5IN88US=>	NXrWS4VuW0GQR1XS
MKN28	M3O4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\3TWM2OD1yLkCzNFEzKM7:TR?=	NF7tcVRUSU6JRWK=
SW837	NXPORnZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPoN\|JmUUN3ME2wMlA{ODF2IN88US=>	M2fYVnNCVkeHUh?=
no-10	MofNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTBwMEOwNVYh\|ryP	NYH0b5ZCW0GQR1XS
BC-3	NFLLdohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWHJS5BVUUN3ME2wMlA{ODF6IN88US=>	M3PBU3NCVkeHUh?=
no-11	MmPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPRTWM2OD1yLkCzNFQ5KM7:TR?=	MkPPV2FPT0WU
8305C	M3rMXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHYbpBuUUN3ME2wMlA{ODd{IN88US=>	MVTTRW5ITVJ?
COLO-679	NFzpdGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfnTWM2OD1yLkCzNVA4KM7:TR?=	MUnTRW5ITVJ?
CESS	MlnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTBwMEOxNkDPxE1?	NV\oWmdLW0GQR1XS
BFTC-909	NWKyUHdjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTBwMEOxNlUh\|ryP	NEXNWVZUSU6JRWK=
MZ2-MEL	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXz4U45HUUN3ME2wMlA{OTd5IN88US=>	M3TiRXNCVkeHUh?=
SW872	M13yTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTBwMEOyNVch\|ryP	NITjPI1USU6JRWK=
LB831-BLC	M2XISmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTBwMEOyNVkh\|ryP	MoX1V2FPT0WU
SK-UT-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX;JR\|UxRTBwMEOyNlEh\|ryP	M{PScnNCVkeHUh?=
NCI-H1734	Mnr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TyfWlEPTB;MD6wN\|I{KM7:TR?=	NWryOHNPW0GQR1XS
OVCAR-8	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\zV2lOUUN3ME2wMlA{OjhzIN88US=>	M1L0O3NCVkeHUh?=
NCI-H2087	MmDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\lT2ZoUUN3ME2wMlA{Ojh7IN88US=>	M4HWNnNCVkeHUh?=
U-87-MG	M4XEUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlPDTWM2OD1yLkCzNlkh\|ryP	MXXTRW5ITVJ?
BC-1	NUPldHhCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1[yNWlEPTB;MD6wN\|M3PyEQvF2=	MVvTRW5ITVJ?
ES7	NWLpWFRCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M13N[mlEPTB;MD6wN\|M4PCEQvF2=	MYnTRW5ITVJ?
Daudi	NWK2RZlsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEnaOXpKSzVyPUCuNFM{PzZizszN	M1vqRXNCVkeHUh?=
RS4-11	M{TUXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTBwMEOzPFMh\|ryP	NFnJWZhUSU6JRWK=
JiyoyeP-2003	M{jLWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mni4TWM2OD1yLkCzN\|g5KM7:TR?=	MX7TRW5ITVJ?
BL-70	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLlTWM2OD1yLkCzN\|g6KM7:TR?=	MmS1V2FPT0WU
OS-RC-2	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTBwMEOzPVYh\|ryP	NHfZfWlUSU6JRWK=
SF268	NYT4U2l7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLXTWM2OD1yLkCzOFAyKM7:TR?=	M3PGXnNCVkeHUh?=
BV-173	M{nQRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1PGUGlEPTB;MD6wN\|QzPiEQvF2=	MYrTRW5ITVJ?
DMS-273	M1PKNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2rV[2lEPTB;MD6wN\|Q4QSEQvF2=	NUHkfI44W0GQR1XS
22RV1	NUDyeXd2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTBwMEO1NFch\|ryP	NIDHZVdUSU6JRWK=
ES8	NFTaWYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTBwMEO1N\|gh\|ryP	NFr4NoRUSU6JRWK=
KYSE-150	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTBwMEO2NFgh\|ryP	NHj2c\|hUSU6JRWK=
HCC1569	NEDTWlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPlTI5WUUN3ME2wMlA{PjB6IN88US=>	MVLTRW5ITVJ?
NB5	Mk\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnj3TWM2OD1yLkCzOlE{KM7:TR?=	NIOw[IVUSU6JRWK=
G-402	NXLBZphMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M375cWlEPTB;MD6wN\|YyPCEQvF2=	MVrTRW5ITVJ?
NCI-H1693	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3fDZWlEPTB;MD6wN\|YyPyEQvF2=	Mke4V2FPT0WU
LB2241-RCC	NIftU4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoXNTWM2OD1yLkCzOlQzKM7:TR?=	MlnGV2FPT0WU
KP-4	NWPyNWRbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn7yTWM2OD1yLkCzOlY{KM7:TR?=	M4\R[HNCVkeHUh?=
ML-2	M{nIT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzVUXJKSzVyPUCuNFM3PzFizszN	NWnCUXZ5W0GQR1XS
KU812	NGHuZ3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PvcmlEPTB;MD6wN\|Y5PCEQvF2=	NGH4dJVUSU6JRWK=
LS-411N	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTG[Gk2UUN3ME2wMlA{PzNzIN88US=>	NHXHTVdUSU6JRWK=
OAW-42	NHLVfndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRTBwMEO3OFch\|ryP	MWrTRW5ITVJ?
HCC38	MorPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2C0TGlEPTB;MD6wN\|c4OSEQvF2=	NIHjdpVUSU6JRWK=
Ca-Ski	NXOyeGRmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWS4SGxyUUN3ME2wMlA{Pzh2IN88US=>	MVvTRW5ITVJ?
Calu-3	M4Lp[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NILOPVBKSzVyPUCuNFM4QDlizszN	NIjDPWtUSU6JRWK=
KYSE-70	NFj3e2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTBwMEO4NVIh\|ryP	MUHTRW5ITVJ?
D-392MG	NXXDPVQyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTBwMEO4OFIh\|ryP	M2HiZ3NCVkeHUh?=
OVCAR-4	NX\UNo1vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{iwNmlEPTB;MD6wN\|g2QCEQvF2=	MV;TRW5ITVJ?
Detroit562	NHzWWVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4n6TGlEPTB;MD6wN\|g4OiEQvF2=	MojxV2FPT0WU
HEL	MoeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEfLcYZKSzVyPUCuNFM5QTFizszN	NX7kUYVPW0GQR1XS
MONO-MAC-6	M1TV[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnuWVJ[UUN3ME2wMlA{QDl\|IN88US=>	NGTZRVlUSU6JRWK=
LoVo	MlHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDE[GJTUUN3ME2wMlA{QTN\|IN88US=>	MVXTRW5ITVJ?
U-2-OS	M37oWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlzHTWM2OD1yLkCzPVM2KM7:TR?=	NYP4T4FsW0GQR1XS
A172	Mn;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTBwMEO5OUDPxE1?	NYfDOYluW0GQR1XS
OCUB-M	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIrDO\|hKSzVyPUCuNFM6PjFizszN	Mle1V2FPT0WU
SW48	M3LMXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoL1TWM2OD1yLkC0NFMyKM7:TR?=	M1HWXnNCVkeHUh?=
HC-1	Mki0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\zd2lEPTB;MD6wOFA3QSEQvF2=	MVXTRW5ITVJ?
KOSC-2	NWPaZo9tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoK5TWM2OD1yLkC0NVEh\|ryP	MkDMV2FPT0WU
HDLM-2	NFfqOnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTBwMESxNVQh\|ryP	MknGV2FPT0WU
CTV-1	MmDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjBZmhjUUN3ME2wMlA1OTF4IN88US=>	M3vDOXNCVkeHUh?=
SH-4	MmfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoGyTWM2OD1yLkC0NVQyKM7:TR?=	NUnYOVk5W0GQR1XS
SW756	NHPlTlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXft[24zUUN3ME2wMlA1OTV5IN88US=>	NYrQeHdzW0GQR1XS
GCT	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\tRWpKSzVyPUCuNFQyPjFizszN	MmjZV2FPT0WU
CHL-1	NYrEW5NkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUf4TFZMUUN3ME2wMlA1OTZ7IN88US=>	NET4d45USU6JRWK=
LAMA-84	NF3R[FNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTBwMESxO\|Eh\|ryP	MYnTRW5ITVJ?
LS-1034	NF:4NmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XMPWlEPTB;MD6wOFE6OSEQvF2=	MXjTRW5ITVJ?
NCI-H358	NV3uR3RbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;xOWlEPTB;MD6wOFIyOiEQvF2=	M4HOTHNCVkeHUh?=
NB13	Mo\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTKTWM2OD1yLkC0NlI4KM7:TR?=	MWrTRW5ITVJ?
TE-9	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH;5cGtKSzVyPUCuNFQzOzdizszN	MV3TRW5ITVJ?
OE33	M4G3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWnrdFdlUUN3ME2wMlA1OjRzIN88US=>	M3;ESXNCVkeHUh?=
CAL-120	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnmTWM2OD1yLkC0NlQyKM7:TR?=	NUnhVoZ3W0GQR1XS
DJM-1	NF:4UG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWrKe5RQUUN3ME2wMlA1Ojd{IN88US=>	NVfjOZBiW0GQR1XS
SK-MEL-24	NWTVWZRiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIPzXlZKSzVyPUCuNFQzQDNizszN	MYTTRW5ITVJ?
VA-ES-BJ	M4KxW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\OPXdQUUN3ME2wMlA1Ojl{IN88US=>	MWXTRW5ITVJ?
MMAC-SF	M{P3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoTUTWM2OD1yLkC0Nlk4KM7:TR?=	MonrV2FPT0WU
MZ7-mel	NYXU[3pUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3XTNWlEPTB;MD6wOFM{KM7:TR?=	NV7FT\|RjW0GQR1XS
BxPC-3	M1TUb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vlV2lEPTB;MD6wOFM1OSEQvF2=	NFfPd29USU6JRWK=
HT-29	M4ryNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTBwMESzOVch\|ryP	NXiwTXFOW0GQR1XS
SK-MEL-30	Mn\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVTTeoh[UUN3ME2wMlA1OzZ{IN88US=>	NXjzWFE2W0GQR1XS
CAL-33	MknFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHPiToNKSzVyPUCuNFQ{PzVizszN	NHzOc\|ZUSU6JRWK=
COLO-680N	NGDjcFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEi5dpFKSzVyPUCuNFQ1ODdizszN	MnnaV2FPT0WU
NH-12	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTBwMES0OEDPxE1?	NFjxWY9USU6JRWK=
HCC1937	Mo\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4GyWmlEPTB;MD6wOFQ2PiEQvF2=	M3qzbHNCVkeHUh?=
IMR-5	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4XMfmlEPTB;MD6wOFQ6KM7:TR?=	MmfQV2FPT0WU
MC-CAR	M4nVZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\XTWM2OD1yLkC0OVY6KM7:TR?=	NW\a[FFXW0GQR1XS
NCI-H747	NHnRZW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3lfXZvUUN3ME2wMlA1PTdizszN	M2rxPHNCVkeHUh?=
NCI-H1792	NH;rbm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTBwMES1PFEh\|ryP	MknzV2FPT0WU
SW13	M3rKdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1HWd2lEPTB;MD6wOFU6KM7:TR?=	NHHLflRUSU6JRWK=
MLMA	NWnTcVBWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{XZU2lEPTB;MD6wOFYxQSEQvF2=	MYXTRW5ITVJ?
U251	NWfORnd5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLFZYVKSzVyPUCuNFQ4PjNizszN	MnKxV2FPT0WU
U031	M3;mSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTBwMES3O\|Eh\|ryP	NV;3WIljW0GQR1XS
ME-180	NWnMNVZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVrJR\|UxRTBwMES3PFIh\|ryP	MoDwV2FPT0WU
SK-MEL-3	NIn5XHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\VcWtKSzVyPUCuNFQ5ODJizszN	NF7Zd\|ZUSU6JRWK=
MOLT-4	NFLCWW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU[4RohYUUN3ME2wMlA1QDB\|IN88US=>	NFTGXXhUSU6JRWK=
PF-382	NHPYTGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nv[WlEPTB;MD6wOFgzPiEQvF2=	NIfPb4ZUSU6JRWK=
NUGC-3	M4Kzcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2GxeWlEPTB;MD6wOFgzPyEQvF2=	NEO2RYRUSU6JRWK=
NCI-H1417	NFm1Z\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlzoTWM2OD1yLkC0PFkh\|ryP	NF7vbGNUSU6JRWK=
COLO-205	Mk\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX2xc\|dEUUN3ME2wMlA1QTF7IN88US=>	Mli2V2FPT0WU
TE-441-T	MnnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXlRnlKSzVyPUCuNFQ6OyEQvF2=	NIe4U4xUSU6JRWK=
MKN1	M3;YbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MULJR\|UxRTBwMES5N{DPxE1?	M3nMPHNCVkeHUh?=
UM-UC-3	NWfVfHRMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1f6PGlEPTB;MD6wOFk2KM7:TR?=	NFG4XpNUSU6JRWK=
SF126	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4PJeWlEPTB;MD6wOVAyKM7:TR?=	NWfXW2JvW0GQR1XS
LB1047-RCC	MkHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnvnTWM2OD1yLkC1NFMyKM7:TR?=	M3TQO3NCVkeHUh?=
A253	M17yeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXG4PHZwUUN3ME2wMlA2ODV{IN88US=>	NETucVhUSU6JRWK=
NCI-H1963	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoTSTWM2OD1yLkC1NVc3KM7:TR?=	MUjTRW5ITVJ?
VM-CUB-1	Ml:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmLKTWM2OD1yLkC1N\|EyKM7:TR?=	M3\MeHNCVkeHUh?=
T-24	NYW1XXkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlvZTWM2OD1yLkC1N\|g1KM7:TR?=	MX3TRW5ITVJ?
K-562	MkPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LyOGlEPTB;MD6wOVM5PyEQvF2=	NUjUU4h[W0GQR1XS
ARH-77	NGTIU5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTBwMEWzPVUh\|ryP	M1f5W3NCVkeHUh?=
CA46	NX\FfJBjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Moq5TWM2OD1yLkC1OFMh\|ryP	NYXKNplXW0GQR1XS
HCC70	MkPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\iTWM2OD1yLkC1OFUzKM7:TR?=	NVzQNYZkW0GQR1XS
ST486	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1XKTmlEPTB;MD6wOVUzPSEQvF2=	NGfW[nRUSU6JRWK=
COLO-741	M1XsdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlzCTWM2OD1yLkC1OVMyKM7:TR?=	M1:zN3NCVkeHUh?=
SK-PN-DW	NGfxXG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTBwMEW1PFgh\|ryP	NX7iVnlvW0GQR1XS
BL-41	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVPzbINVUUN3ME2wMlA2PTl4IN88US=>	MmXOV2FPT0WU
D-263MG	NEjJOIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTBwMEW2PFMh\|ryP	NYftWZo3W0GQR1XS
KE-37	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlK1TWM2OD1yLkC1Olg{KM7:TR?=	NH7sZ\|RUSU6JRWK=
LU-134-A	NUL4WJpOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTBwMEW3NVUh\|ryP	M2f0eHNCVkeHUh?=
HCC2157	NUfsN\|dxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVvpNnIzUUN3ME2wMlA2PzN\|IN88US=>	M3exOHNCVkeHUh?=
GAK	NFLLWnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTBwMEW3N\|Qh\|ryP	NYnwbZByW0GQR1XS
IST-SL2	Mm\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmHRTWM2OD1yLkC1O\|Q{KM7:TR?=	NGX1cHZUSU6JRWK=
KMOE-2	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHv6RlZKSzVyPUCuNFU4PDlizszN	NUL5[\|YzW0GQR1XS
SW1573	MojPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3Pjd2lEPTB;MD6wOVgxOiEQvF2=	MUHTRW5ITVJ?
SCC-9	NFHzT4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIDtdYVKSzVyPUCuNFU5PyEQvF2=	NUDudWFbW0GQR1XS
MDA-MB-361	NX3uOIEyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LmPGlEPTB;MD6wOVg4OiEQvF2=	MlvnV2FPT0WU
BHT-101	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWrOdW91UUN3ME2wMlA2QDd4IN88US=>	M{n0SnNCVkeHUh?=
NCI-H1770	NEXze4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEK1TGVKSzVyPUCuNFU5PzlizszN	NGG0RlJUSU6JRWK=
UACC-893	NGP4fXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{\IW2lEPTB;MD6wOVg6PiEQvF2=	NVzSTIlSW0GQR1XS
NCI-H226	NXGxUmtOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4T2SmlEPTB;MD6wOVk5QCEQvF2=	NY\0d4Z4W0GQR1XS
HLE	NHTsW\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkXHTWM2OD1yLkC2NFgzKM7:TR?=	NFPj[mJUSU6JRWK=
NCI-H1703	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYS3WVRWUUN3ME2wMlA3OTd6IN88US=>	NWTsWVV7W0GQR1XS
KURAMOCHI	NIDrVZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3K3UGlEPTB;MD6wOlE5QSEQvF2=	MUfTRW5ITVJ?
RH-1	MnW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1fKW2lEPTB;MD6wOlI{KM7:TR?=	NXvCdWUyW0GQR1XS
DSH1	NID5[pRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGj4UoVKSzVyPUCuNFYzPyEQvF2=	MkDsV2FPT0WU
CAMA-1	NHPxNmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTBwME[zNFMh\|ryP	NW\Ie3Q6W0GQR1XS
NCI-H1437	NVHSW2F5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MonQTWM2OD1yLkC2N\|I5KM7:TR?=	NGG0eoJUSU6JRWK=
HuP-T4	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1Hs[mlEPTB;MD6wOlU5PiEQvF2=	M3fQV3NCVkeHUh?=
HCT-15	M2DzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTBwME[1PVch\|ryP	NX\RUGpLW0GQR1XS
NCCIT	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoO3TWM2OD1yLkC2OlA1KM7:TR?=	NV;uS3d[W0GQR1XS
BOKU	M{D0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWXY[JhHUUN3ME2wMlA3Pjd2IN88US=>	MUfTRW5ITVJ?
FADU	MmP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTBwME[3OFUh\|ryP	MULTRW5ITVJ?
SUP-T1	M{j3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTGTWM2OD1yLkC2O\|Yh\|ryP	NFvIcGRUSU6JRWK=
L-363	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTBwME[5NFEh\|ryP	MoLlV2FPT0WU
KNS-81-FD	NFzJZWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfhTWM2OD1yLkC2PVE5KM7:TR?=	MULTRW5ITVJ?
SU-DHL-1	MlfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2P5RWlEPTB;MD6wOlkzKM7:TR?=	MUPTRW5ITVJ?
HuH-7	Mn;pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGTOVWtKSzVyPUCuNFcxOzVizszN	Ml\aV2FPT0WU
BT-474	NILhToRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoC4TWM2OD1yLkC3NFYyKM7:TR?=	NX23[HlFW0GQR1XS
CAPAN-1	NVHue3plT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIDFUVFKSzVyPUCuNFcyPDNizszN	MnfNV2FPT0WU
HEC-1	M33oT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2WxOGlEPTB;MD6wO\|E3OSEQvF2=	MlXUV2FPT0WU
NOMO-1	NIHsNVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjXV4lKSzVyPUCuNFcyPzJizszN	NGLueIVUSU6JRWK=
KM-H2	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXrEVIo3UUN3ME2wMlA4OjRzIN88US=>	MofnV2FPT0WU
EB2	M37CRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVTxfW1GUUN3ME2wMlA4Ojh3IN88US=>	NEHZZ49USU6JRWK=
LU-99A	MkLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2frUmlEPTB;MD6wO\|I5PyEQvF2=	NEOzb\|hUSU6JRWK=
WSU-NHL	Moe4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTUTWM2OD1yLkC3N\|I6KM7:TR?=	MUTTRW5ITVJ?
Calu-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH33[ZpKSzVyPUCuNFc{OzJizszN	NX\Eb3ZVW0GQR1XS
U-698-M	NXnl[VhtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHuTGg5UUN3ME2wMlA4Ozh{IN88US=>	M1\MPHNCVkeHUh?=
T98G	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLsTWM2OD1yLkC3OFIyKM7:TR?=	MkXiV2FPT0WU
GI-ME-N	NGP5NWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUPuOYJzUUN3ME2wMlA4PDJ4IN88US=>	MWXTRW5ITVJ?
LS-513	MlGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTBwMEe0OVYh\|ryP	MkT5V2FPT0WU
UACC-257	NVLC[41[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2fFNGlEPTB;MD6wO\|UxPSEQvF2=	MlTQV2FPT0WU
DK-MG	NETRNVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;ycGlEPTB;MD6wO\|UzPiEQvF2=	NFjGNWhUSU6JRWK=
EW-11	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFPQepRKSzVyPUCuNFc2OzVizszN	M13SbnNCVkeHUh?=
CHP-126	M3;ZZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M17FfmlEPTB;MD6wO\|U3PSEQvF2=	Mlf4V2FPT0WU
Saos-2	M2XT[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2O5TmlEPTB;MD6wO\|U6PyEQvF2=	M3vJ[3NCVkeHUh?=
Ramos-2G6-4C10	M2K1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFrSN3ZKSzVyPUCuNFc3PDhizszN	NYq0Z45NW0GQR1XS
L-428	M4WwcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWrmdGhOUUN3ME2wMlA4PzB2IN88US=>	NX:1U2hHW0GQR1XS
HOP-92	NWjGXY9oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWPkeoVEUUN3ME2wMlA4PzFzIN88US=>	MkD2V2FPT0WU
PANC-08-13	NFr1OGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXVfmNKSzVyPUCuNFc4OTZizszN	M1vNZ3NCVkeHUh?=
TUR	NXK2ZYdqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\nR2lEPTB;MD6wO\|c{OyEQvF2=	MlrLV2FPT0WU
DMS-153	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn:1TWM2OD1yLkC3O\|M2KM7:TR?=	Mo\LV2FPT0WU
NCI-N87	NXzz[5hbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlTRTWM2OD1yLkC3O\|k6KM7:TR?=	M2GyWnNCVkeHUh?=
ESS-1	NGnRTYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIPZcZdKSzVyPUCuNFc5PjhizszN	MlHOV2FPT0WU
CP66-MEL	NYm1VXFsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHhTWM2OD1yLkC3PFg4KM7:TR?=	MUfTRW5ITVJ?
NCI-SNU-1	NVHVc2E2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTBwMEe4PFgh\|ryP	NXvvTY1TW0GQR1XS
Calu-6	NYHpT4xRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVHWb4JVUUN3ME2wMlA4QTZ3IN88US=>	NVHITYQ3W0GQR1XS
COLO-668	M2q3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1H2UmlEPTB;MD6wO\|k5PCEQvF2=	MmTMV2FPT0WU
SK-CO-1	MnrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PEcGlEPTB;MD6wO\|k6OiEQvF2=	NFzQZ3NUSU6JRWK=
NCI-H2347	NEPyZ4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTBwMEiwNlgh\|ryP	NVHlTWpkW0GQR1XS
CAL-27	NFvZV4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTBwMEixOVYh\|ryP	MnjwV2FPT0WU
COLO-684	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInYWXZKSzVyPUCuNFgyPThizszN	Ml;PV2FPT0WU
LNCaP-Clone-FGC	MkLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2Lab2lEPTB;MD6wPFE3PSEQvF2=	M4HnbHNCVkeHUh?=
NCI-H1304	NYXxVYRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnXqTWM2OD1yLkC4NlcyKM7:TR?=	MXzTRW5ITVJ?
KP-N-YS	NH7jcndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEPBRoJKSzVyPUCuNFg{PDVizszN	M37heHNCVkeHUh?=
CP50-MEL-B	NWTDc4c{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRTBwMEizOlgh\|ryP	M2L2b3NCVkeHUh?=
LAN-6	MmjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fHRWlEPTB;MD6wPFQ6QCEQvF2=	M13qPHNCVkeHUh?=
ABC-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPZTWM2OD1yLkC4O\|U6KM7:TR?=	MkH0V2FPT0WU
ES3	NYS3OpQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTBwMEi3OlMh\|ryP	M121fHNCVkeHUh?=
COLO-792	MlriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1q4VWlEPTB;MD6wPFg2PSEQvF2=	M4TVN3NCVkeHUh?=
J-RT3-T3-5	NFv5[oZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlnxTWM2OD1yLkC4PVY5KM7:TR?=	NH\kPHJUSU6JRWK=
EFO-21	M4rkbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkC3TWM2OD1yLkC4PVkyKM7:TR?=	NF32fINUSU6JRWK=
MDA-MB-231	NVPQeVQyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFrNWo1KSzVyPUCuNFkxQDJizszN	NGntU5ZUSU6JRWK=
SBC-5	M4PKOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzSUnhKSzVyPUCuNFkyQTNizszN	NU\GSlB7W0GQR1XS
SAS	NHzxb3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnfyTWM2OD1yLkC5NlE2KM7:TR?=	MYjTRW5ITVJ?
SNU-387	NEjQUFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHFTWM2OD1yLkC5NlE5KM7:TR?=	MlzxV2FPT0WU
EVSA-T	NWrmTHBjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnfDTWM2OD1yLkC5NlY2KM7:TR?=	Mm\HV2FPT0WU
MHH-PREB-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnTaTWM2OD1yLkC5N\|Eh\|ryP	NUTnNmJwW0GQR1XS
KARPAS-45	NGL3fHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjOeGpKSzVyPUCuNFk{PDVizszN	M4jBUHNCVkeHUh?=
SJRH30	NGK5OXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTBwMEm0OFQh\|ryP	MVTTRW5ITVJ?
JEG-3	Mm\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUP1c5NlUUN3ME2wMlA6PTB3IN88US=>	M4rUR3NCVkeHUh?=
NB12	M4XleGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{\Bc2lEPTB;MD6wPVUyQCEQvF2=	M{XjbXNCVkeHUh?=
HCC1419	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3Hv[GlEPTB;MD6wPVU1OSEQvF2=	MlfCV2FPT0WU
HCC1599	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M17xV2lEPTB;MD6wPVYxOSEQvF2=	NYnkWnRzW0GQR1XS
IPC-298	M4jQVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkPmTWM2OD1yLkC5OlQ1KM7:TR?=	Ml21V2FPT0WU
MPP-89	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYPTPGlNUUN3ME2wMlA6PzJzIN88US=>	MoTKV2FPT0WU
HT-1376	MnvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmL4TWM2OD1yLkC5PFYyKM7:TR?=	MnzIV2FPT0WU
MDA-MB-468	M4XSU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnrqTWM2OD1yLkC5PVg2KM7:TR?=	NITuRWVUSU6JRWK=
HCC2218	NUXlVYxJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVO0WFR5UUN3ME2wMlA6QTl7IN88US=>	MYHTRW5ITVJ?
LK-2	NX64c29NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnmTWM2OD1yLkGwNVc3KM7:TR?=	Ml;MV2FPT0WU
GR-ST	MmLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4DjSGlEPTB;MD6xNFIyKM7:TR?=	M{PiNXNCVkeHUh?=
PFSK-1	NIHFPHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlzzTWM2OD1yLkGwNlY4KM7:TR?=	M32yU3NCVkeHUh?=
NCI-H2052	M4Duemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWDQOXQ2UUN3ME2wMlExPDB5IN88US=>	MYLTRW5ITVJ?
A673	NWTJSnR4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjJTWM2OD1yLkGwOFMyKM7:TR?=	NYP3Z2V2W0GQR1XS
EKVX	NGXXRZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3LUUmlEPTB;MD6xNFQ5OyEQvF2=	NFnw[oJUSU6JRWK=
23132-87	MkHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTBwMUC0PFgh\|ryP	MlXQV2FPT0WU
EW-18	MmXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{X0dGlEPTB;MD6xNFYxPCEQvF2=	NFHYVFVUSU6JRWK=
KU-19-19	NWjVSY9WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;GfWlEPTB;MD6xNFgyPyEQvF2=	NWTFPGVNW0GQR1XS
NCI-H441	M13GPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTBwMUC4PVkh\|ryP	NFTzV5RUSU6JRWK=
COLO-824	NEfpSJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnxXXZKSzVyPUCuNVExOiEQvF2=	M{\FWHNCVkeHUh?=
HCC1806	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF3w[W1KSzVyPUCuNVEyODhizszN	Mo\DV2FPT0WU
SK-MM-2	NWrNelIyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEP0cllKSzVyPUCuNVEyPDVizszN	M1fBWnNCVkeHUh?=
DEL	Ml2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVHG[FhkUUN3ME2wMlEyOTl{IN88US=>	NX31UI9IW0GQR1XS
NCI-H661	MkG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIHHN5hKSzVyPUCuNVEyQTVizszN	MoLKV2FPT0WU
LC4-1	MkXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTBwMUG0OlYh\|ryP	MWPTRW5ITVJ?
BEN	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWntemQyUUN3ME2wMlEyPjB5IN88US=>	NVX1RZNXW0GQR1XS
RPMI-8226	NGfFTG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRTBwMUG3NVkh\|ryP	NVPuVGIyW0GQR1XS
AU565	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2rsemlEPTB;MD6xNVg{OSEQvF2=	NFvHTHdUSU6JRWK=
CAS-1	NIP0TGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mon3TWM2OD1yLkGxPVY1KM7:TR?=	MlHFV2FPT0WU
UACC-62	Mn3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlnGTWM2OD1yLkGyNVIh\|ryP	NGH5c2FUSU6JRWK=
C-4-II	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWHiSoR1UUN3ME2wMlEzOTdizszN	NW\KVoRmW0GQR1XS
DMS-53	M3jteWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUnqcXdCUUN3ME2wMlEzOjd4IN88US=>	Mlf4V2FPT0WU
SK-MEL-2	M3PQc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\iTWM2OD1yLkGyOFYh\|ryP	M2\TUXNCVkeHUh?=
S-117	M3SwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTBwMUK2O\|Qh\|ryP	MU\TRW5ITVJ?
ChaGo-K-1	M1fnRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWrwNmh4UUN3ME2wMlEzPjl7IN88US=>	MYjTRW5ITVJ?
KMS-12-PE	Mmf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUK5c4lSUUN3ME2wMlEzQDZ7IN88US=>	MXHTRW5ITVJ?
PC-3	M1PLV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3njSmlEPTB;MD6xN\|E4PyEQvF2=	M{jRNHNCVkeHUh?=
RERF-LC-MS	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYmz[lF[UUN3ME2wMlE{PDNizszN	M3jTO3NCVkeHUh?=
GMS-10	Ml\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmHwTWM2OD1yLkGzOFQ1KM7:TR?=	MWXTRW5ITVJ?
CTB-1	NV\GXGF[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHKdFJKSzVyPUCuNVM1PjlizszN	M2\iWXNCVkeHUh?=
SCC-25	MlfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlyzTWM2OD1yLkGzOVg5KM7:TR?=	NXTSRY56W0GQR1XS
NCI-H1755	MlnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTBwMUO4Nlch\|ryP	MXXTRW5ITVJ?
D-542MG	NHH1THdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRTBwMUO5OlUh\|ryP	MYPTRW5ITVJ?
KARPAS-422	NELlZnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTBwMUSwN\|ch\|ryP	NFHwPYlUSU6JRWK=
OVCAR-3	NFTTPWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjad3JJUUN3ME2wMlE1ODd6IN88US=>	NGH1XHBUSU6JRWK=
NCI-H1092	Mke4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfPVGFKSzVyPUCuNVQyODFizszN	MVHTRW5ITVJ?
HH	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTBwMUSyNFEh\|ryP	MlXyV2FPT0WU
NB1	M4TzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWjRcmdKUUN3ME2wMlE1PDJ4IN88US=>	Mof5V2FPT0WU
HD-MY-Z	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1XT[mlEPTB;MD6xOFQzQSEQvF2=	MX7TRW5ITVJ?
SHP-77	NUHkOW5nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUGwWodKUUN3ME2wMlE1PDd{IN88US=>	MVLTRW5ITVJ?
U-266	NEPnUZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\ZT2dDUUN3ME2wMlE1PDhizszN	M33IWXNCVkeHUh?=
GI-1	M4XwXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHzTWM2OD1yLkG0O\|czKM7:TR?=	M1vNZ3NCVkeHUh?=
NCI-H1522	Ml\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzQTWM2OD1yLkG0O\|g4KM7:TR?=	M3LqT3NCVkeHUh?=
647-V	MlewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnzGTWM2OD1yLkG0PVQzKM7:TR?=	MX;TRW5ITVJ?
HCT-116	M4XweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4S2cmlEPTB;MD6xOVE3QSEQvF2=	MV;TRW5ITVJ?
NCI-H2081	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M17FSGlEPTB;MD6xOVIyQCEQvF2=	MXnTRW5ITVJ?
THP-1	NIrVV3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{[w[WlEPTB;MD6xOVM{OyEQvF2=	Mn\LV2FPT0WU
LU-165	M{Pld2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3nRXWlEPTB;MD6xOVQyOyEQvF2=	NXjOe5Z4W0GQR1XS
RCM-1	NITCe\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYP6NpNWUUN3ME2wMlE2PjhizszN	MljDV2FPT0WU
COR-L279	NXvRXXo6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jXWGlEPTB;MD6xOVg{PiEQvF2=	NEDWcndUSU6JRWK=
SK-NEP-1	NYXnNpdrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{LufWlEPTB;MD6xOVg6QSEQvF2=	NHvt[25USU6JRWK=
KLE	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoX2TWM2OD1yLkG2NVY6KM7:TR?=	NEHnT25USU6JRWK=
NCI-H2170	M1KzZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2DPN2lEPTB;MD6xOlMxPCEQvF2=	Mk[2V2FPT0WU
TGW	NVT5UXJjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnP3TWM2OD1yLkG2OFcyKM7:TR?=	MWjTRW5ITVJ?
CAL-72	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{nkdWlEPTB;MD6xOlU6KM7:TR?=	NFrlSmpUSU6JRWK=
K052	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmTjTWM2OD1yLkG3NFYyKM7:TR?=	M12yNHNCVkeHUh?=
COR-L88	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnwTWM2OD1yLkG3NVE1KM7:TR?=	MYfTRW5ITVJ?
HSC-4	Mn\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{LzOGlEPTB;MD6xO\|E3KM7:TR?=	M2rrOHNCVkeHUh?=
GOTO	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnrKTWM2OD1yLkG3NlQ3KM7:TR?=	MWDTRW5ITVJ?
MEG-01	M3vh[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV3JR\|UxRTBwMUeyOVch\|ryP	NEPJZXFUSU6JRWK=
MDA-MB-134-VI	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrPWo9KSzVyPUCuNVc{PjdizszN	NUH5eG1{W0GQR1XS
NCI-H596	M3KxR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFjDSXpKSzVyPUCuNVc{QCEQvF2=	MV;TRW5ITVJ?
EW-3	MojlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\5S2hKSzVyPUCuNVc1QDZizszN	M4HLNnNCVkeHUh?=
NCI-H1573	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTBwMUe2O\|gh\|ryP	MWjTRW5ITVJ?
SKG-IIIa	NVuyT3JoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXHCZW9iUUN3ME2wMlE4QDB5IN88US=>	M3Szb3NCVkeHUh?=
SK-N-DZ	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTBwMUe4PFMh\|ryP	MX;TRW5ITVJ?
EGI-1	MkDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUHJR\|UxRTBwMUe5O{DPxE1?	MWjTRW5ITVJ?
COLO-320-HSR	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1zZdmlEPTB;MD6xPFQ6OyEQvF2=	NFzOPVJUSU6JRWK=
DOHH-2	M1LreGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MonQTWM2OD1yLkG4OVY6KM7:TR?=	M{TnbXNCVkeHUh?=
MS-1	NVrnToJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHfOT4VKSzVyPUCuNVg3KM7:TR?=	MYDTRW5ITVJ?
NCI-H2171	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;6XmlEPTB;MD6xPFY1QSEQvF2=	Mn\zV2FPT0WU
NCI-H526	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml[xTWM2OD1yLkG4Olk3KM7:TR?=	MYTTRW5ITVJ?
MDA-MB-415	NE\CfXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfqdY9KSzVyPUCuNVk4PDhizszN	NFzuXW1USU6JRWK=
ECC4	Ml61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTBwMUm4OlMh\|ryP	MXvTRW5ITVJ?
C2BBe1	NHHFeXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PwcmlEPTB;MD6xPVg6OyEQvF2=	NIn4cJhUSU6JRWK=
TE-11	M4TMVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIHk[VlKSzVyPUCuNVk6PzVizszN	MkDpV2FPT0WU
LU-65	NWPTSm5xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2HsWWlEPTB;MD6yNFIyOSEQvF2=	M3XabnNCVkeHUh?=
MKN45	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;KRYJKSzVyPUCuNlA3PCEQvF2=	NILPRWdUSU6JRWK=
TGBC1TKB	NITzRpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPseYpuUUN3ME2wMlIxQTl5IN88US=>	MkTJV2FPT0WU
NCI-H2196	NYraXlE1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYDSe5ZnUUN3ME2wMlIyPzR5IN88US=>	M2TCOHNCVkeHUh?=
M14	Moq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1juV2lEPTB;MD6yNVgxOyEQvF2=	NVS2b\|U{W0GQR1XS
NCI-H1436	NE[2VFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\TTWlEPTB;MD6yNVgzPiEQvF2=	M3\5d3NCVkeHUh?=
EB-3	M4nTNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEHCOmpKSzVyPUCuNlI{PzZizszN	M2DmXHNCVkeHUh?=
HT	Mo\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYryXGxkUUN3ME2wMlIzPTZ4IN88US=>	M3jrXnNCVkeHUh?=
A3-KAW	NELRVVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLMW5hKSzVyPUCuNlI4ODhizszN	NFqwV3RUSU6JRWK=
DB	M4HhSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYXUenNUUUN3ME2wMlIzQDZ3IN88US=>	MUHTRW5ITVJ?
KARPAS-299	MmLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVqzZnhZUUN3ME2wMlIzQTl2IN88US=>	M{\WdXNCVkeHUh?=
IM-9	MkmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1\QOmlEPTB;MD6yN\|Q4PiEQvF2=	MXvTRW5ITVJ?
NCI-H838	MkDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGqxVppKSzVyPUCuNlM4OTRizszN	MUnTRW5ITVJ?
NB10	M{O3dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTBwMkO3N\|Eh\|ryP	MVnTRW5ITVJ?
NCI-H2141	NH3BOJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTBwMkO4OFEh\|ryP	Mkn3V2FPT0WU
LB647-SCLC	MmXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTBwMkSwNVQh\|ryP	NGS0TWhUSU6JRWK=
NCI-H23	M4DHPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIj1WFVKSzVyPUCuNlQxPTlizszN	NH\WNVFUSU6JRWK=
MN-60	NU\2OnpZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NESySGdKSzVyPUCuNlQzOzlizszN	NVP4Wm1MW0GQR1XS
CAL-148	NXzwZZp[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEi3OZlKSzVyPUCuNlQzQDJizszN	NICzeJhUSU6JRWK=
EFE-184	NWDFPJVqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXLDSmllUUN3ME2wMlI1PTl5IN88US=>	M4HaPXNCVkeHUh?=
TE-6	NXz5dXk6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIDNWZVKSzVyPUCuNlQ3OTJizszN	M3HZfXNCVkeHUh?=
SN12C	NW\HbXg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWmybGp1UUN3ME2wMlI1Pjl2IN88US=>	M1jnUHNCVkeHUh?=
CAKI-1	NV;CeYhsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2mwSGlEPTB;MD6yOVA5PiEQvF2=	MX3TRW5ITVJ?
MHH-NB-11	NYq2fXB5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDoTWM2OD1yLkK1N\|Uh\|ryP	NUnhdVJzW0GQR1XS
DOK	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFHzPZdKSzVyPUCuNlU6OyEQvF2=	NUfTfJJuW0GQR1XS
Raji	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTBwMk[2NFMh\|ryP	NH\IOGVUSU6JRWK=
OAW-28	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFjPWWxKSzVyPUCuNlY3PzdizszN	MVTTRW5ITVJ?
P30-OHK	Mk\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HSTWlEPTB;MD6yOlkxPSEQvF2=	M2rWeHNCVkeHUh?=
NCI-H69	NUnlZ40zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\JR\|UxRTBwMkeyNFEh\|ryP	NGX5T4dUSU6JRWK=
SK-N-AS	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXizU\|ZNUUN3ME2wMlI4OjJizszN	NW\4eIFCW0GQR1XS
BE-13	M4rWbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzZXndzUUN3ME2wMlI4OjR7IN88US=>	M3zLTnNCVkeHUh?=
NCI-H1618	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M36w[WlEPTB;MD6yO\|UyKM7:TR?=	NInFVmNUSU6JRWK=
NCI-SNU-5	NVzoWlJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\0bHhKSzVyPUCuNlc3OTNizszN	NVPaPJVqW0GQR1XS
NCI-H1694	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIDLVGdKSzVyPUCuNlc4OzNizszN	MoG1V2FPT0WU
RL	NUDOd4dFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGXi[YlKSzVyPUCuNlgyPzRizszN	NWXqXZU1W0GQR1XS
SW684	NV;BNZRYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRTBwMkizPFMh\|ryP	MX\TRW5ITVJ?
EW-24	M1fjcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzTZmFTUUN3ME2wMlI5QDFizszN	NHPWT25USU6JRWK=
NCI-H510A	MojNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1v6ZWlEPTB;MD6yPVMxPCEQvF2=	NW\XUGZOW0GQR1XS
Mo-T	Mo\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1jibWlEPTB;MD6yPVM{OSEQvF2=	M3nhenNCVkeHUh?=
LB373-MEL-D	NIrDPW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PIOGlEPTB;MD6yPVQ{OSEQvF2=	MlnqV2FPT0WU
NCI-H28	NHvYNIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXnMZlluUUN3ME2wMlI6QDN5IN88US=>	MVHTRW5ITVJ?
NCI-H446	NVrTbld3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHXsWHdKSzVyPUCuNlk6OjFizszN	MluzV2FPT0WU
L-540	M3fiWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn3ETWM2OD1yLkOwNFg6KM7:TR?=	NELtNmZUSU6JRWK=
MKN7	MlHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmLyTWM2OD1yLkOwOlM6KM7:TR?=	MkjiV2FPT0WU
OPM-2	NVrKXVBVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3JbphKSzVyPUCuN\|ExPjRizszN	NV;OTVRkW0GQR1XS
BT-20	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPEOpNKSzVyPUCuN\|ExQTlizszN	NF\qfYpUSU6JRWK=
KP-N-YN	NWnZb\|Y4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{PT[WlEPTB;MD6zNVEyQCEQvF2=	NXizXpd7W0GQR1XS
MDA-MB-175-VII	M1jlbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzEZW9KSzVyPUCuN\|I{PDhizszN	M1G1ZXNCVkeHUh?=
EFM-19	MoTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTBwM{OxN\|Ih\|ryP	NIHlb2NUSU6JRWK=
COLO-678	Ml3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWfzRlFvUUN3ME2wMlM{Ozh7IN88US=>	NXm4TJhbW0GQR1XS
COLO-829	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnz4TWM2OD1yLkO0OFUzKM7:TR?=	NXXaOlhYW0GQR1XS
A704	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1TqOGlEPTB;MD6zOFkzOyEQvF2=	NF3PUHpUSU6JRWK=
NCI-H719	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTBwM{WxNlQh\|ryP	MWHTRW5ITVJ?
MFE-280	NEfwXVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MojiTWM2OD1yLkO1O\|E2KM7:TR?=	Ml\IV2FPT0WU
DMS-114	MlzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn;4TWM2OD1yLkO2NVIh\|ryP	M1rSWnNCVkeHUh?=
RMG-I	Ml7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPnOJNKSzVyPUCuN\|Y3QTFizszN	NIj0N\|ZUSU6JRWK=
SK-N-FI	MlyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fEVWlEPTB;MD6zO\|Y{PyEQvF2=	M3\kenNCVkeHUh?=
LB2518-MEL	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWjZR4NXUUN3ME2wMlQxQDd{IN88US=>	NWHOcHZxW0GQR1XS
IST-MES1	M2Lp[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnG2TWM2OD1yLkSxNUDPxE1?	M1XJT3NCVkeHUh?=
HPAF-II	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTBwNEGxNVch\|ryP	MnWzV2FPT0WU
NCI-H1882	NH\wRYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;RRnZKSzVyPUCuOFE4QDRizszN	Ml\CV2FPT0WU
JVM-2	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIPuNVRKSzVyPUCuOFQ1ODFizszN	MXTTRW5ITVJ?
T47D	NIHBTVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRTBwNES1Nlgh\|ryP	NXm0WVB[W0GQR1XS
MHH-CALL-2	NEfjbHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7WN\|FKSzVyPUCuOFQ5OyEQvF2=	NHzOOldUSU6JRWK=
NCI-H716	MnOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4H5VGlEPTB;MD60OFg1QCEQvF2=	M3vO[3NCVkeHUh?=
NEC8	NHXlNXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTBwNEWxOFUh\|ryP	NVf3[HBjW0GQR1XS
UACC-812	NWXmWnd[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHTtbXFKSzVyPUCuOFY4PzZizszN	NX\v[npwW0GQR1XS
D-502MG	NXXVbWxOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rZb2lEPTB;MD60PFA{KM7:TR?=	M1nxPXNCVkeHUh?=
CaR-1	NGLhd4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGq0fnhKSzVyPUCuOVA{PjdizszN	M1[4S3NCVkeHUh?=
LU-139	NXXLVFFnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHITWM2OD1yLkWxOFU4KM7:TR?=	Mk\hV2FPT0WU
RPMI-8402	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4q0fmlEPTB;MD61NlIxPyEQvF2=	M1LNVnNCVkeHUh?=
SW1088	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEDGb4FKSzVyPUCuOVM5PjlizszN	M2TFR3NCVkeHUh?=
JVM-3	NIHZWoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYDuNmwxUUN3ME2wMlU1OTF5IN88US=>	M4T1SHNCVkeHUh?=
YAPC	M{j4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHjG[2xKSzVyPUCuOVUzOTFizszN	MYXTRW5ITVJ?
KG-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTBwNUW5PFQh\|ryP	MX7TRW5ITVJ?
C32	Mn;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHTkS4RKSzVyPUCuOVc{OTNizszN	NVrmZZpXW0GQR1XS
IST-SL1	NWjkdZhRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DsSWlEPTB;MD62NFQ{PSEQvF2=	MYDTRW5ITVJ?
NCI-H2126	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVn1RoM2UUN3ME2wMlY{OTV{IN88US=>	MUjTRW5ITVJ?
HCC1954	M4TOU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHUTWM2OD1yLk[0O\|I3KM7:TR?=	MXnTRW5ITVJ?
WM-115	NWTLdnF6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;ZTWM2OD1yLk[1NFkzKM7:TR?=	NEnUSZFUSU6JRWK=
NB6	NGPuZWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmrUTWM2OD1yLk[3N\|M2KM7:TR?=	NWrpPHk3W0GQR1XS
TYK-nu	M4D1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTBwNke5OVIh\|ryP	MnPUV2FPT0WU
KY821	MlrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEHi[mJKSzVyPUCuO\|AzOjlizszN	NEHFXVdUSU6JRWK=
SIMA	M4jtfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTBwN{G3NVkh\|ryP	MVrTRW5ITVJ?
RCC10RGB	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTBwN{G5NVgh\|ryP	MlzHV2FPT0WU
LN-405	NFnXT2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnsTWM2OD1yLke0N\|Yh\|ryP	Mlm1V2FPT0WU
NCI-H1155	NFL0VmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIDVfo9KSzVyPUCuO\|Q5PjhizszN	MoXHV2FPT0WU
SCLC-21H	MnnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVzhcGxJUUN3ME2wMlc3QTB\|IN88US=>	M4nXZ3NCVkeHUh?=
DMS-79	NFLLbXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1\NZ2lEPTB;MD63O\|g1PSEQvF2=	NYHy[ZN5W0GQR1XS
EC-GI-10	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXj2T3hMUUN3ME2wMlc4QTd3IN88US=>	MkTOV2FPT0WU
KNS-42	NX7YZVhuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2juN2lEPTB;MD63PFg{OSEQvF2=	M4DpN3NCVkeHUh?=
SNU-475	M3rIUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfxTWM2OD1yLke5NlAzKM7:TR?=	MnSyV2FPT0WU
SF539	NFvQS2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTBwN{m5NlUh\|ryP	NXuxSnZjW0GQR1XS
SW1417	M3\uZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1L2d2lEPTB;MD64NVM{QSEQvF2=	M4PTW3NCVkeHUh?=
ATN-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1zXUGlEPTB;MD64OVEyPSEQvF2=	NUnTWGhvW0GQR1XS
PLC-PRF-5	M4DpUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVvxUpIzUUN3ME2wMlg5PDd3IN88US=>	Mmq0V2FPT0WU
HT-3	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXrOTGZuUUN3ME2wMlg6PDJizszN	NXvRWYJiW0GQR1XS
MDA-MB-453	NUHjVGZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGC4cZlKSzVyPUCuPVA{ODRizszN	M2LJeXNCVkeHUh?=
HAL-01	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjIOnZKSzVyPUCuPVk{PzlizszN	NIq3WFhUSU6JRWK=
NCI-H1993	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{i5OmlEPTB;MT6wOFY2PyEQvF2=	NUDOSWFRW0GQR1XS
NCI-H2227	NX;KOI1[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYq3U4V[UUN3ME2xMlA1QThzIN88US=>	Mm\TV2FPT0WU
LP-1	M1fXcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4nuVGlEPTB;MT6wOlk{KM7:TR?=	MknyV2FPT0WU
P31-FUJ	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXvJR\|UxRTFwMUC3OlYh\|ryP	MofTV2FPT0WU
NCI-H64	NHnVSY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrjTVlrUUN3ME2xMlE2PDJizszN	M1\Q[HNCVkeHUh?=
SW1463	M3;CVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MliyTWM2OD1zLkG4N\|Q6KM7:TR?=	M4LVfnNCVkeHUh?=
SK-MEL-1	NIPQb5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTFwMkC1PVUh\|ryP	NHLZR\|RUSU6JRWK=
TALL-1	NI\tNpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFjPXo5KSzVyPUGuNlUyPjVizszN	M3i0[3NCVkeHUh?=
RO82-W-1	NITMdWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7NTWM2OD1zLkOzN\|M6KM7:TR?=	M2TCcHNCVkeHUh?=
NCI-H1581	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnOXYVKSzVyPUGuN\|U3QDdizszN	MkC4V2FPT0WU
NCI-H748	NYTx[3hmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGjKbmtKSzVyPUGuN\|U4OzhizszN	MWTTRW5ITVJ?
HCC1187	NILPVHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjySo9LUUN3ME2xMlU2PTJ{IN88US=>	NYntblI3W0GQR1XS
EoL-1-cell	M2XJeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2TDUWlEPTB;MT61PFg5QSEQvF2=	NXP6S4U3W0GQR1XS
HuO-3N1	NUHYPJhZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXPhTGp2UUN3ME2xMlg{PDF{IN88US=>	M2rybXNCVkeHUh?=
NCI-H1793	M3zqRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTubFFzUUN3ME2xMlg4PTl\|IN88US=>	MUjTRW5ITVJ?
Caov-3	NFfTeJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmjvTWM2OD1{LkCwOlI2KM7:TR?=	MWHTRW5ITVJ?
JAR	NFzvc\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPlTWM2OD1{LkC3PVIh\|ryP	M3HJTnNCVkeHUh?=
SK-MEL-28	NVHCfpdNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTJwMUiwPVgh\|ryP	MVHTRW5ITVJ?
EM-2	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnW5TWM2OD1{LkKwNlk{KM7:TR?=	MlTMV2FPT0WU
Mewo	NXzHSpRtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;odWlEPTB;Mj6yNlI3PSEQvF2=	MUjTRW5ITVJ?
NCI-H720	NVnTOXA1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYWyOG1yUUN3ME2yMlI3PTh3IN88US=>	MXXTRW5ITVJ?
CAL-54	M4K5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1q2UmlEPTB;Mj6yOlc6PSEQvF2=	MV;TRW5ITVJ?
MC116	MmfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkTUTWM2OD1{LkO2N\|k4KM7:TR?=	NGfZUpNUSU6JRWK=
DG-75	MorFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTJwNEi1O\|Yh\|ryP	Mkf1V2FPT0WU
HCC1143	MlPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnnNTWM2OD1{LkWwOlU5KM7:TR?=	MY\TRW5ITVJ?
FTC-133	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHnEXmFKSzVyPUKuOVM3QDlizszN	NF\reJNUSU6JRWK=
AsPC-1	M2rIVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn:zTWM2OD1{LkWzPVI6KM7:TR?=	MWHTRW5ITVJ?
NCI-H889	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFf4bWhKSzVyPUKuOVY4ODZizszN	NYPMTFR{W0GQR1XS
HT55	NHrXNmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHL3dpBKSzVyPUKuOlIxOTlizszN	NWqwVJB{W0GQR1XS
UMC-11	NWjGUoFJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXHFWHE3UUN3ME2yMlc5PzF3IN88US=>	M4nIZnNCVkeHUh?=
P12-ICHIKAWA	MnTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTJwOEKwOFYh\|ryP	NGXWdG9USU6JRWK=
HCC1395	NXO5eYtXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MleyTWM2OD1{Lkm4OlAzKM7:TR?=	NGHwfXZUSU6JRWK=
D-283MED	M2rHZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGPzOmxKSzVyPUOuNVg6OzdizszN	MXTTRW5ITVJ?
COLO-800	NVvnU5c5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF3XPXZKSzVyPUOuN\|M5QTdizszN	NFzxW49USU6JRWK=
MFM-223	MmHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1HyemlEPTB;Mz6zOlA6PyEQvF2=	NVPKXZZGW0GQR1XS
TE-5	NF61TWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTRwNU[xOFch\|ryP	NFnQ[phUSU6JRWK=
NCI-H209	NI\ocXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIf5bG5KSzVyPUSuO\|g2PzJizszN	MnmzV2FPT0WU
SiHa	NX;Sd5BtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGjHNGtKSzVyPUSuPVUzODNizszN	NE\KbnRUSU6JRWK=
NCI-H1395	M1TWUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTVwMUC2N\|Mh\|ryP	NXK4V5J{W0GQR1XS
A498	Mn3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmXvTWM2OD13LkKxNlUyKM7:TR?=	NHq1OnRUSU6JRWK=
ES5	NYS3PYw1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFnldGRKSzVyPUWuOlEyPzhizszN	MlnGV2FPT0WU
MDA-MB-157	NGWySJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVe2V\|dyUUN3ME21MlY3PDR\|IN88US=>	Mm\MV2FPT0WU
NCI-H1623	NHvrRo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIH5VWhKSzVyPUWuPFM2PTZizszN	NF63fo1USU6JRWK=
RPMI-8866	NG\3NXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlvBTWM2OD13Lki0O\|kzKM7:TR?=	MVnTRW5ITVJ?
LC-1F	MnfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3XjZWlEPTB;Nj6wPVI6OSEQvF2=	NVXCcGl5W0GQR1XS
TCCSUP	NGXSdoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{jM[GlEPTB;Nj62NFM1QSEQvF2=	NYrpeY1mW0GQR1XS
TT	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mli4TWM2OD16LkOzNFA6KM7:TR?=	MYjTRW5ITVJ?
NCI-H1838	NWn1eGM5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7xXWF{UUN3ME24MlUyPzNzIN88US=>	M3PvcHNCVkeHUh?=
NCI-H322M	M4i0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVr4SFU1UUN3ME25MlE3OjhzIN88US=>	NVT2[Y54W0GQR1XS
NCI-H187	NYXmSXA{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVvSNHlyUUN3ME25MlUyQDN3IN88US=>	Mmn6V2FPT0WU
SBC-1	M{jNVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfPcHlkUUN3ME25Mlk{PjV4IN88US=>	MY\TRW5ITVJ?
SCC-3	Mn;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIPFXJBKSzVyPUGwMlU3PzlizszN	NUTtSHQyW0GQR1XS
SW948	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjHTWM2OD1zMD63OVEyKM7:TR?=	NWLVSXhPW0GQR1XS
CPC-N	MlTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIiySVZKSzVyPUGxMlAxPyEQvF2=	NX\5O2tXW0GQR1XS
TGBC24TKB	M4[0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUTNbopCUUN3ME2xN{42OjlizszN	NWf6cIZQW0GQR1XS
NCI-H2452	NEfsepRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTF2LkezJO69VQ>?	MVLTRW5ITVJ?
Hs-578-T	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4XmcGlEPTB;MUiuOVc2QSEQvF2=	M1;i[3NCVkeHUh?=
DV-90	NWjKNXhJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NITQUVdKSzVyPUG4Mlk6PDVizszN	NUO1fnFHW0GQR1XS
NCI-H1563	NFHiTXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTF7Lke4PFgh\|ryP	M3;0OnNCVkeHUh?=
SW780	M1qxPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTJzLkGzNVgh\|ryP	MUXTRW5ITVJ?
NCI-H345	M2L6OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknlTWM2OD1{MT64O\|c6KM7:TR?=	NUXSdmdVW0GQR1XS
LB771-HNC	NFzKOY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmG2TWM2OD1{Mj60PFE{KM7:TR?=	MUXTRW5ITVJ?
RT4	NHricGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTJ\|LkOyPFIh\|ryP	Mn;ZV2FPT0WU
NCI-H82	MlfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWPRVYpwUUN3ME2yN{42PTJ4IN88US=>	MV3TRW5ITVJ?
NCI-H524	Mlu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTJ2LkO4NVIh\|ryP	MX;TRW5ITVJ?
SNU-C1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXv3d41tUUN3ME2yOE46OTB3IN88US=>	NI\ocWZUSU6JRWK=
NCI-SNU-16	NVj4Nm9LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37Nd2lEPTB;NEiuN\|E1OiEQvF2=	M2mw[nNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-ALK / ALK / p-AKT / AKT / p-ERK / ERK / TβRI / TβRII; PubMed: 23993685 Mol Oncol Cells were treated with or without the indicated doses of 17-DMAG or AUY-922 for 3 h. Changes in ALK-related signaling and TGF-b receptors were analyzed using Western blot analysis. The densitometry values were determined relative to control of H2228 after normalization to b-actin protein. E-cadherin / Cleaved PARP / Bim; PubMed: 23993685 Mol Oncol Cells were treated with crizotinib (1 mM), 17-DMAG (1 mM), or AUY-922 (1 mM) for the indicated times. Cell lysates were subjected to Western blot analysis using the indicated antibodies. The densitometry values were determined relative to control after normalization to b-actin protein. HSP70 / Grp94 / Grp78 / p-eIF2α / CHOP / IRE1α / p-JNK; PubMed: 24796583 Oncotarget CCA cells were incubated with 0.5 uM NVP-AUY922 for 0, 2, 4, 8, 16, and 24 h. Whole cell lysates were subjected to western blot analysis for HSP70, Grp94, Grp78, p-eIF2α, CHOP, IRE1α, and phosphor-JNK. β-Actin was used as the loading control. CDK4 / HMGA2 ; PubMed: 26893968 PeerJ HCT116 cells were treated with NVP-AUY922 at the indicated concentrations for 48 hours. Cell extracts were analyzed using Western blotting with the antibodies for CDK4, Hsp70, and HMGA2, respectively.	23993685 24796583 26893968
Growth inhibition assay	Cell viability; PubMed: 26893968 PeerJ Cell viability assay was performed to determine the of HCT116 cells treated with various concentrations of NVP-AUY922 for 48 hours. p < 0.05, p < 0.01, **p < 0.001. All experiments were performed in three independent experiments.	26893968

In vivo

Treatment with NVP-AUY922 causes a robust antitumor response and inhibits p-Akt and VEGF expression in an HSC-2 xenograft model. ^[2] In BT474, NVP-AUY922 shows complete loss of ERBB2 and substantial depletion of ERα, in addition to reductions in CDK4 and phospho-ERK1/2. ^[3]

Protocol

Kinase Assay:^[3]	- Collapse Kinase assay: NVP-AUY922 is dissolved in DMSO at a concentration of 10 mM. NVP-AUY922 is assessed against HSP90α, HSP90β, GRP94, TRAP-1, HSP72, and topoisomerase II. Profiling against a panel of kinases has been carried out and screening against a panel of additional enzymes and receptors is performed at Cerep.
Cell Research:^[1]	- Collapse Cell lines: Human gastric cancer cells NCI-N87 Concentrations: 1 μM Incubation Time: 3 days Method: Human gastric cancer cells NCI-N87 (5-7 ×10³ in 50 μL/well) are seeded in 96-well plates and incubated at 37 °C for 24 hours, followed by NVP-AUY922 treatment for 1-3 days at 37 °C. After treatment, the cells are assayed by MTT method and analyzed by microplate reader. (Only for Reference)
Animal Research:^[3]	- Collapse Animal Models: Female NCr athymic mice bearing WM266.4 human melanoma xenografts Dosages: 50 mg/kg Administration: Administered via i.v. or i.p. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	93 mg/mL warmed (199.76 mM)
	Water	Insoluble
	Ethanol	''31 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 1% DMSO+30% polyethylene glycol+1% Tween 80 For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Luminespib (NVP-AUY922) SDF

Molecular Weight	465.54
Formula	C₂₆H₃₁N₃O₅
CAS No.	747412-49-3
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	AUY-922
Smiles	CCNC(=O)C1=NOC(=C1C2=CC=C(C=C2)CN3CCOCC3)C4=CC(=C(C=C4O)O)C(C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01772797	Completed	Drug: LDK378\|Drug: AUY922	Anaplastic Lymphoma Kinase (ALK)\|Non-small Cell Lung Cancer	Novartis Pharmaceuticals\|Novartis	June 2013	Phase 1
NCT01752400	Completed	Drug: AUY922	Non Small Cell Lung Cancer	Massachusetts General Hospital	January 2013	Phase 2
NCT01613950	Completed	Drug: AUY922\|Drug: BYL719	Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein	Novartis Pharmaceuticals\|Novartis	December 2012	Phase 1
NCT01484860	Terminated	Drug: AUY922	Adenocarcinoma of the Pancreas\|Metastatic Disease	University Health Network Toronto\|Novartis Pharmaceuticals	January 2012	Phase 2
NCT01402401	Terminated	Drug: AUY922 + Trastuzumab	Advanced Gastric Cancer	Novartis Pharmaceuticals\|Novartis	November 2011	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

HSP (HSP90) Signaling Pathway Map

HSP (HSP90) Inhibitors with Unique Features

Selective HSP90 Inhibitor

NVP-BEP800 : HSP90β-selective, IC50=58 nM.
Most Potent HSP90 Inhibitor

KW-2478 : HSP90, IC50=3.8 nM.
HSP90 Inhibitor in Clinical Trial

17-AAG (Tanespimycin) : Phase III for Gastrointestinal Stromal Tumors.
Newest HSP90 Inhibitor

XL888 : ATP-competitive inhibitor of HSP90 with IC50 of 24 nM.

Related HSP (HSP90) Products

PU-H71 ^New

PU-H71 is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.
KNK437 ^New

KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.
VER155008 ^New

VER-155008 is a potent Hsp70 family inhibitor with IC50 of 0.5 μM, 2.6 μM, and 2.6 μM in cell-free assays for HSP70, HSC70, and GRP78, respectively, >100-fold selectivity over HSP90. VER155008 inhibits autophagy and causes reduced levels of HSP90 client proteins.
Tanespimycin (17-AAG)

Tanespimycin (17-AAG, CP127374, NSC-330507, KOS 953) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Tanespimycin (17-AAG) induces apoptosis, necrosis, autophagy and mitophagy. Phase 3.

Features:Displays very low toxicity toward normal cells.
Ganetespib (STA-9090)

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Alvespimycin (17-DMAG) HCl

Alvespimycin (17-DMAG, NSC 707545, BMS 826476, KOS 1022) HCl is a potent HSP90 inhibitor with IC50 of 62 nM in a cell-free assay. Phase 2.

Features:A synthetic derivative Geldanamycin, with lower hepatotoxicity than parent antibiotic & higher potency and bioavailability than the similar derivative 17-AAG.
Geldanamycin

Geldanamycin (NSC 122750) is a natural existing HSP90 inhibitor with K_d of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association. Geldanamycin attenuates virus infection-induced ALI (acute lung injury)/ARDS (acute respiratory distress syndrome) by reducing the host's inflammatory responses.
HSP990 (NVP-HSP990)

HSP990 (NVP-HSP990) is a novel, potent and selective HSP90 inhibitor for HSP90α/β with IC50 of 0.6 nM/0.8 nM. NVP-HSP990 induces cell cycle arrest and apoptosis.

Features:NVP-HSP990 is an orally available HSP90 inhibitor and is structurally distinct from other clinical HSP90 inhibitors.
Elesclomol (STA-4783)

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
Onalespib (AT13387)

Onalespib (AT13387) is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Luminespib (NVP-AUY922)